Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $156.45, for a total transaction of $18,148.20. Following the sale, the director directly owned 11,316 shares in the company, valued at $1,770,388.20. This trade represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, June 22nd, Musa Tariq sold 1,951 shares of Guardant Health stock. The shares were sold at an average price of $131.16, for a total value of $255,893.16.
• On Tuesday, June 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $130.19, for a total value of $15,102.04.

Guardant Health Stock Performance

Shares of GH opened at $160.12 on Wednesday. The stock has a 50-day moving average of $151.74 and a two-hundred day moving average of $117.58. Guardant Health, Inc. has a one year low of $53.40 and a one year high of $176.58. The stock has a market cap of $21.49 billion, a P/E ratio of -45.88 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same period in the prior year, the company posted ($0.44) earnings per share. The firm’s revenue for the quarter was up 44.3% on a year-over-year basis. Analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Guardant Health by 2.1% in the 4th quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock valued at $1,242,101,000 after purchasing an additional 251,939 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after buying an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. grew its position in Guardant Health by 14.9% during the fourth quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after buying an additional 435,232 shares during the period. Geode Capital Management LLC grew its position in Guardant Health by 9.4% during the fourth quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in Guardant Health by 3.0% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Royal Bank Of Canada raised their price target on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Sanford C. Bernstein increased their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, July 2nd. Piper Sandler raised their target price on shares of Guardant Health from $135.00 to $193.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Citigroup boosted their target price on shares of Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, TD Cowen upped their price target on shares of Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.